ClinicalTrials.Veeva

Menu

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

Alcon logo

Alcon

Status and phase

Completed
Phase 3

Conditions

Open-Angle Glaucoma
Ocular Hypertension

Treatments

Drug: Alcon Investigational Agent

Study type

Interventional

Funder types

Industry

Identifiers

NCT00047541
C-01-70

Details and patient eligibility

About

To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems